Back to top
more

National Vision (EYE)

(Real Time Quote from BATS)

$13.80 USD

13.80
1,294,049

+0.60 (4.55%)

Updated Aug 5, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.

Bruker (BRKR) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid CALID Group growth potential and raised 2021 financial guidance.

AMN Healthcare (AMN) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

AMN Healthcare (AMN) is optimistic about maintaining its strength in staffing service as well as offering a broad array of services.

Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study

by Zacks Equity Research

Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.

Reasons to Add HealthEquity Stock (HQY) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about HealthEquity (HQY) on its slew of buyouts and strength in HSA.

    Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia

    by Zacks Equity Research

    Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.

      Philips (PHG) Recalls CPAP, Ventilators Used for Sleep Apnea

      by Zacks Equity Research

      Philips (PHG) is recalling some Bi-Level PAP, CPAP, and mechanical ventilator devices in the United States due to health risks.

      Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT

      by Zacks Equity Research

      Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.

      The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health

      5 Probable MedTech Winners Post-COVID on Discounted PEG

      by Zacks Equity Research

      Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.

      The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein

      Bruker (BRKR) FluoroType Assay Detects New SARS-CoV-2 Variants

      by Zacks Equity Research

      Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.

      Urmimala Biswas headshot

      5 MedTech Stocks to Gain in 2021 as Base Business Recovers

      by Urmimala Biswas

      These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.

      Sejuti Banerjea headshot

      Brokers Like These Growth Stocks, and So Do We

      by Sejuti Banerjea

      One way to make money from the stock market is by following the experts.

      Here's Why You Should Retain LHC Group (LHCG) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of buyouts and a broad array of services.

      Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

      by Zacks Equity Research

      Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

      Medtronic's (MDT) STROKE AF Trial Outcome Backs ICM Progress

      by Zacks Equity Research

      STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.

      Why You Should Add Veeva Systems (VEEV) to Your Portfolio

      by Zacks Equity Research

      Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

      Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up

      by Zacks Equity Research

      Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.

      IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm

      by Zacks Equity Research

      The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.

      PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension

      by Zacks Equity Research

      PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.

      Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows

      by Zacks Equity Research

      The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.

      QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS

      by Zacks Equity Research

      QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.

      Integra (IART) Tissue Technologies Rebounds Amid Supply Woe

      by Zacks Equity Research

      Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

      Walgreens' (WBA) New Partnerships Aid, Retail Sales Dip

      by Zacks Equity Research

      Walgreens Boots' (WBA) response toward combatting the pandemic - conducting COVID-19 tests at various locations and actively participating in vaccinating residents and staff - is impressive.